The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Two New p73 Splice Variants, γ and δ, with Different Transcriptional Activity
Open accessAbstract
p73 has been recently identified as a new structural and functional homologue of the transcription factor p53. It is expressed in either a full-length form, α, or a shorter β mRNA variant, with exon 13 spliced out. Here we report the identification and functional characterization of two new p73 splicing variants, γ (splicing out exon 11) and δ (splicing out exons 11, 12, and 13). Both γ and δ p73 variants are expressed in human peripheral blood lymphocytes, primary keratinocytes, and different tumor cell lines, including neuroblastoma, glioblastoma, melanoma, hepatoma, and leukemia. The expression pattern of the four p73 splicing variants differs in both primary cells of different lineage and established cell lines even within the same type of tumor. A two-hybrid assay was used to characterize the homodimeric and heterodimeric interactions between the p73 variants, and showed that neither p73γ nor p73δ interact with p53, whereas p73γ showed strong interactions with all p73 isoforms, and p73δ binds efficiently p73α and p73γ but only weakly p73β. At the functional level, p73γ is significantly less efficient in activating transcription of the p21Waf1/Cip1 promoter than p53 or p73β, whereas the effect of p73δ is intermediate and comparable to that of p73α. The ability of the different p73 variants to affect cell growth in p53 null osteosarcoma SAOS-2 cells correlates with their transcriptional activity on the p21Waf1/Cip1 promoter: p73β is the most efficient in inhibiting colony formation, whereas p73γ is almost ineffective. Our results suggest that p73 isoforms may be differentially regulated, with four different isoforms capable of interacting among themselves and with p53. The relative expression level of each splice variant may modulate p73 transcriptional and growth suppression activities by affecting heterodimer formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“To exert most if not all of its functions, p53 acts as a transcriptional activator on numerous genes that contain specific DNA-binding sequences on their promoter, such as p21 Waf1/Cip1 (8, 9) and gadd45 (10), or as a transcription repressor on genes that do not contain such sequences, probably by sequestering transcr…”
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K., Signer, S. H., Davidson, N., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,733
Ko, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
p73 is a human p53-related protein that can induce apoptosis
Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Michalovitz, D., Halevy, O., & Oren, M. (1990) · Cell · doi:10.1016/0092-8674(90)90113-s · Cited by 769
Binding and modulation of p53 by p300/CBP coactivators
Lill, N. L., Grossman, S. R., Ginsberg, D., DeCaprio, J., & Livingston, D. M. (1997) · Nature · doi:10.1038/42981 · Cited by 693
Recruitment of p300/CBP in p53-Dependent Signal Pathways
Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S., & Kelly, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80304-9 · Cited by 669
Synergistic activation of transcription by CBP and p53
Gu, W., Shi, X.-L., & Roeder, R. G. (1997) · Nature · doi:10.1038/42972 · Cited by 596
Santhanam, U., Ray, A., & Sehgal, P. B. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.17.7605 · Cited by 375
Takeuchi, M., Rothe, M., & Goeddel, D. V. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19935 · Cited by 301
Transcriptional activation by p53 correlates with suppression of growth but not transformation
CROOK, T. (1994) · Cell · doi:10.1016/0092-8674(94)90071-x · Cited by 233
Nomoto, S., Haruki, N., Kondo, M., Konishi, H., Takahashi, T., Takahashi, T., & Takahashi, T. (1998) · PubMed · Cited by 175
Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M., & Aloni, Y. (1993) · PubMed · Cited by 159
Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma.
Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S., & Nakagawara, A. (1998) · PubMed · Cited by 142
Tumor Necrosis Factor (TNF) Receptor 1 Signaling Downstream of TNF Receptor-associated Factor 2
Natoli, G., Costanzo, A., Moretti, F., Fulco, M., Balsano, C., & Levrero, M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.42.26079 · Cited by 124
Self-citationLonely No More: p53 Finds Its Kin in a Tumor Suppressor Haven
Oren, M. (1997) · Cell · doi:10.1016/s0092-8674(00)80347-5 · Cited by 83
Cytogenetic studies in primary and metastatic neuroendocrine merkel cell carcinoma
Sozzi, G., Bertoglio, M. G., Pilotti, S., Rilke, F. O., Pierotti, M. A., & Porta, G. D. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90104-5 · Cited by 51
Apoptosis and the cell cycle: the p53 connection
Choisy, C., & Yonish-Rouach, E. (1998) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400339 · Cited by 51
Clurman, B. E., & Groudine, M. T. (1997) · Nature · doi:10.1038/38116 · Cited by 38
Cited by
Yang, A., Walker, N., Bronson, R., Kaghad, M., Oosterwegel, M., Bonnin, J., Vagner, C., Bonnet, H., Dikkes, P., Sharpe, A., et al. (2000) · Nature · doi:10.1038/35003607 · Cited by 990
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Self-citationRole for the p53 homologue p73 in E2F-1-induced apoptosis
Irwin, M., Marin, M. C., Phillips, A. C., Seelan, R. S., Smith, D. I., Liu, W., Flores, E. R., Tsai, K. Y., Jacks, T., Vousden, K. H., et al. (2000) · Nature · doi:10.1038/35036614 · Cited by 710
The p53/p63/p73 family of transcription factors: overlapping and distinct functions
Levrero, M., Laurenzi, V. D., Costanzo, A., Sabatini, S., Gong, J., Wang, J. Y. J., & Melino, G. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.10.1661 · Cited by 565
Self-citationp73: Friend or foe in tumorigenesis
Melino, G., De Laurenzi, V., & Vousden, K. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc861 · Cited by 560
Self-citation
Metadata
- Authors
- De Laurenzi, V., Costanzo, A., Barcaroli, D., Terrinoni, A., Falco, M., Annicchiarico-Petruzzelli, M., Levrero, M., & Melino, G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1998-11-02
- Volume
- 188
- Issue
- 9
- Pages
- 1763-1768
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1982121839
- Cited by
- 368
- References
- 25
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.